NCT07211932尚未招募不适用
Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.
Consorci Sanitari de l'Alt Penedès i Garraf3 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2025年12月1日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 58
- 试验地点
- 3
- 主要终点
- JADAS-10
研究概览
简要总结
This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Tofacitinib
Patients affected by JIA and treated with tofacitinib
干预措施: Tofacitinib (Drug)
结局指标
主要结局
JADAS-10
时间窗: Baseline and 12 months
Change in the Juvenile Arthritis Disease Activity Score (JADAS-10) score at 12 months of treatment with tofacitinib. Range score: 0 to 10, the less score the better
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
Enrolling By Invitation
4 期
Efficacy and Safety of Tofacitinib in Refractory Blau SyndromeBlau SyndromeNCT06660329Peking Union Medical College Hospital30
已完成
3 期
Efficacy Study Of Tofacitinib In Pediatric JIA PopulationJuvenile Idiopathic ArthritisNCT02592434Pfizer225
已完成
4 期
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia AreataAlopecia AreataNCT03800979Institute of Dermatology, Thailand19
招募中
不适用
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisUlcerative ColitisjRCT2071210075Pfizer Japan Inc.120
已完成
4 期
effectiveness of tofacitinib in moderate to severe ulcerative colitis compared to steroidCTRI/2023/09/057448Shankar Roy94